Showing 1 - 12 of 19 reports matching: Tumour
Journals
Specialties
Date of Publication
to
Synopsis: 7 randomized controlled trials with 2,529 patients with histologically confirmed osteosarcoma were included in this meta-analysis. The purpose of this study was to compare the safety and efficacy of ifosfamide-based chemotherapy to a control group receiving chemotherapy without ifosfamide. The results displayed Read More »
Level 1 Meta Analysis
Synopsis: 40 patients with skeletal metastasis who were scheduled to undergo local radiotherapy were included in this study. The purpose of the study was to determine the effect of zoledronate, a bisphosphonate, in collagen breakdown and bone loss secondary to radiation therapy. Patients were randomized Read More »
Level 2 RCT
Synopsis: 497 postmenopausal women with hormone-receptor-positive breast cancer were randomized to receive adjuvant exemestane 25 mg or anastrozole 1 mg daily for 5 years. Two subgroups were identified: those with baseline T-scores of -2.0 or greater at the spine and hip (subgroup 1), and those with baseline T-scores less than -2.0 at the spine and hip and taking bisphosphonates (subgroup 2). Results at 2 Read More »
Author verified Level 2 RCT
Synopsis: 645 patients with castration-resistant prostate cancer and bone metastases were randomized to either early administration of zoledronic acid or standard administration of zoledronic acid initiated following progression to castration-sensitive disease. The purpose was to determine whether early treatment would reduce time to developing a skeletal-related event (SREs) compared to standard treatment. Results indicated similar Read More »
Level 2 RCT
Synopsis: 1404 patients with bone metastases from breast cancer were randomized to receive treatment with either oral ibandronic acid or intravenous zoledronic acid. The frequency and timing of skeletal-related events (SREs) was the primary non-inferiority endpoint. After 96 weeks Read More »
Level 2 RCT
Synopsis: 67 women with non-metastatic breast cancer (Stage I-III) experiencing joint pain attributed to the use of aromatase inhibitor (AI) were included in this study. Subjects were randomized to an intervention group, or a wait list control (WLC) group. Those randomized to Read More »
Author verified Level 1 RCT
Synopsis: 1,779 patients with solid tumours (except breast and prostate) or myeloma, as well as at least 1 bone metastasis or osteolytic lesion as confirmed by radiographic imaging were randomized to receive either monthly subcutaneous injections of denosumab or intravenous administration of zoledronic acid to compare the efficacy and safety of these two treatments. Results at 34 months indicated that denosumab was noninferior when compared to zoledronic acid, and both groups yielded similar overall survival rates, disease progression, and safety. The zoledronic acid Read More »
Author verified Level 1 RCT
Synopsis: 134 patients with metastatic bone disease and a vertebral compression fracture (VCF) were randomized to be treated with either balloon kyphoplasty or a standard non-surgical treatment (control group) to compare the effects of these treatments on pain, function and quality of life. Results indicated that the kyphoplasty group had significantly better improvements in function, quality of life, reduced activity days, bed rest days, and analgesic consumption compared to the control group at 1 month. The kyphoplasty group Read More »
Author verified Level 2 RCT
Synopsis: 1960 patients with multiple myeloma were randomized to undergo either intensive or non-intensive treatment. Within each treatment type patients were further randomized to receive either zoledronic acid intravenously or clodronic acid orally, in order to determine which bisphosphonate and treatment type was more effective in lowering the danger of skeletal-related events. Following assessments over Read More »
Author verified Level 2 RCT
Synopsis: 234 patients with nonmetastatic osteosarcoma were randomized to preoperative chemotherapy of high-dose methotrexate with either doxorubicin or with etoposide and ifosfamide. After a median of 77-month follow-up, patients who had received the etoposide-ifosfamide regimen exhibited a larger percentage of good histologic response. Three- and 5-year Read More »
Author verified Level 2 RCT
Synopsis: 602 postmenopausal women receiving adjuvant letrozole were randomized either to upfront zoledronic acid or delayed-start zoledronic acid to determine which method minimizes bone-loss. At 5 years Read More »
Author verified Level 2 RCT
Synopsis: 662 osteosarcoma patients without detectable metastatic disease were either randomized to three drug (cisplatin, doxorubicin, methotrexate) or four drug chemotherapy (cisplatin, doxorubicin, methotrexate, and ifosfamide). A further comparison was conducted on the effects of the addition muramyl tri-peptide (MTP) to both chemotherapy regimens. Four- and six-year Read More »
Author verified Level 2 RCT